Sandbox reserved 1651
From Proteopedia
(Difference between revisions)
Line 36: | Line 36: | ||
The [https://en.wikipedia.org/wiki/Retinitis_pigmentosa Retinitis pigmentosa] is a hereditary disease. The patient loses progressively a part of his sight: Night vision as a teenager, side vision as a young adult and central vision in later life. This loss of sight is due to the progressive decrease of rod and cone photoreceptor cells which provide coloured vision. Scientists observed that symptoms appear many years after the beginning of the photoreceptor’s degeneration in most cases. Retinitis pigmentosa can be encoded by many genes. More than 45 have been identified but these genes concern only 60% of sick patients. Therefore 40% of cases of Retinitis pigmentosa are unidentified genes. Until today there is no cure. But studies showed a slow down of the disease with the intake of vitamin A palmitate foods and omega-3-rich fish [2]. | The [https://en.wikipedia.org/wiki/Retinitis_pigmentosa Retinitis pigmentosa] is a hereditary disease. The patient loses progressively a part of his sight: Night vision as a teenager, side vision as a young adult and central vision in later life. This loss of sight is due to the progressive decrease of rod and cone photoreceptor cells which provide coloured vision. Scientists observed that symptoms appear many years after the beginning of the photoreceptor’s degeneration in most cases. Retinitis pigmentosa can be encoded by many genes. More than 45 have been identified but these genes concern only 60% of sick patients. Therefore 40% of cases of Retinitis pigmentosa are unidentified genes. Until today there is no cure. But studies showed a slow down of the disease with the intake of vitamin A palmitate foods and omega-3-rich fish [2]. | ||
- | For instance, <scene name='87/872232/Subunit_dhdds/1'>DHDDS</scene> missense mutations can provoke an autosomal recessive Retinitis pigmentosa (arRP). These mutations concern the S1 and S2 sites of the active site where pyrophosphate can bind and most of the mutations related to the disease impact directly the substrate binding, according to scientists. For one mutation, <scene name='87/872232/K42/3'>K42E</scene>, it is more complicated. Scientists remarked that, in the | + | For instance, <scene name='87/872232/Subunit_dhdds/1'>DHDDS</scene> missense mutations can provoke an autosomal recessive Retinitis pigmentosa (arRP). These mutations concern the S1 and S2 sites of the active site where pyrophosphate can bind and most of the mutations related to the disease impact directly the substrate binding, according to scientists. For one mutation, <scene name='87/872232/K42/3'>K42E</scene>, it is more complicated. Scientists remarked that, in the <scene name='87/872232/Salt_bridge_k42-e234/1'>wild type, R38 points toward the active-site cavity, while K42 and E234 form a stable salt bridge</scene> (short distance). The mutation K42E provokes in the protein scale, hypothetically, an interaction with the adjacent active-site residues R38 positively charged. So R38 points away from the active site cavity, forming a new stable [[salt bridge]] with the mutant E42. The distance between K42E and E234 is longer due to the charge repulsion. Finally, experiments proved that aberrant polar networks are due to the K42E mutation, disturbing the active-site residues which can’t interact with the substrate and leading to a decrease of the catalytic activity [1]. |
Revision as of 20:54, 16 February 2021
Heterotetrameric Cis-Prenyltransferase Complex
|
References
[1] Michal Lisnyansky Bar-El et al. «Structural basis of heterotetrameric assembly and disease mutations in the human cis-prenyltransferase ». Nature Communications. 11:523, (2020).
[2 ]Dyonne T Hartong et al. « Retinitis Pigmentosa ». The Lancet. 18;368(9549):1795‑809, (2006)